Melanoma

  • ECOG E3611- A Phase II Randomized Study of Ipilimumab at 3mg/kg or 10mg/kg Alone or in Combination with High Dose Interferon-a in Advanced Melanoma
  • RTOG 0631- A Phase II/III Randomized Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis
  • ECOG E1609- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon Alfa-2b for Resected High-risk Melanoma Treatment- Arm A is closed
  • ECOG E3612- A Phase II Randomized Study of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma